The company estimates that its install base surpassed 15,000 by the end of last year, leading to sales of more than $20 ...

Get all the news you need in your inbox each morning. The medical service/device: The iLet Bionic Pancreas, an insulin pump. The service provider: CCS, a medical supplies distributor. The bill ...

Beta Bionics (BBNX) leads innovation in the diabetes treatment market with its groundbreaking iLet Bionic Pancreas technology ...

"Beta Bionics joins IPO uptick, aims to raise $114.4m in Nasdaq listing" was originally created and published by Medical ...

Irvine-based medical device company Beta Bionics Inc. on Jan. 6 filed an S-1 with the Securities and Exchange Commission to list on the Nasdaq under the symbol “BBNX.” ...

Beta Bionics, Inc. (BBNX) is planning to raise $112 million in an initial public offering on Thursday, January 30th, IPO Scoop reports. The company will be issuing 7,500,000 shares at $14.00-$16.00 ...

Underwriters have a 30-day option to buy an additional 1.8 million shares. Beta Bionics also agreed to sell 1 million shares ...

Beta Bionics announced today that it went public after pricing a significantly upsized initial public offering (IPO).

Beta Bionics (BBNX), a maker of insulin delivery devices, has disclosed terms for an upsized $113M initial public offering. Read more here.

Beta Bionics today filed a prospectus outlining its aim to bring in $114.4 million in its initial public offering (IPO).

The iLet device was designed to improve glycemic ... Beta is also in the early stages of development of an 'insulin pump that is designed to adhere directly to the skin and administer insulin ...